Innovation, technology and digitisation have been tipped as the top trends and priorities for the life science industries.
The trends were compiled and released by not-for-profit The Pistoia Alliance based on the ‘The Life Sciences Innovation Report’ developed with Clarivate Analytics.
According to the report, multi-disciplinary innovation, the implementation of new technologies, new approaches to research, the digitisation of R&D and healthcare, and academic contributions to biologics drug R&D are all key trends in the life sciences industry.
“One of the aims of The Pistoia Alliance has always been to support life science companies, and one way we do this is by helping organisations set their R&D priorities and plan their investments,” said Steve Arlington, President of The Pistoia Alliance.
“Members of The Pistoia Alliance benefit from exclusive access to information from us and our partners – the Clarivate Analytics report is a good example of this.
“Given the Alliance’s primary goal of increasing collaboration within the life science industry and with other sectors, we are not surprised to see the link between the key trends for next year is the need for co-operation and input from a range of disciplines.”
Key trends and priorities
- Innovation is being driven via collaboration from multiple industry stakeholders
The emergence and development of new tools like nanosensors, bi-specific antibodies and computational biology have highlighted the success that can be achieved from collaboration between researchers and organisations across a range of disciplines. This trend which will continue in 2019.
- Technologies are bring adopted to advance drug research
The report findings show budgets will continue to increase to allow for new technological advances, including the use of artificial intelligence in R&D decision making. Research from The Pistoia Alliance has already shown growth in the implementation of AI and blockchain
- New types of research are coming to the forefront
Research in precision medicine, immunotherapy and the microbiome are opening up new discovery pathways. Alongside genomic research, these new approaches will provide a more refined understanding of diseases, better diagnoses and improvements to treatment.
- Digitisation of R&D and healthcare will increase
R&D functions are already beginning to adopt large-scale use of cloud-based platforms, but this will accelerate this year. Mobile computing is poised to support the digitisation of health in combination with drug therapy, as well as through stand-alone therapies.
- Academia is increasingly contributing to biologics R&D
Academia has already made significant contributions to scientific innovation across genetic and cellular therapies, with antibodies, CAR-T and CRISPR-Cas9 all leading to new approaches to potential novel biological therapies. The role of academia will become more vital as researchers look to expand on existing research.